SG11201504946VA - Histone demethylase inhibitors - Google Patents

Histone demethylase inhibitors

Info

Publication number
SG11201504946VA
SG11201504946VA SG11201504946VA SG11201504946VA SG11201504946VA SG 11201504946V A SG11201504946V A SG 11201504946VA SG 11201504946V A SG11201504946V A SG 11201504946VA SG 11201504946V A SG11201504946V A SG 11201504946VA SG 11201504946V A SG11201504946V A SG 11201504946VA
Authority
SG
Singapore
Prior art keywords
histone demethylase
demethylase inhibitors
inhibitors
histone
demethylase
Prior art date
Application number
SG11201504946VA
Inventor
Young K Chen
Toufike Kanouni
Zhe Nie
Jeffrey Alan Stafford
James Marvin Veal
Michael Brennan Wallace
Original Assignee
Quanticel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quanticel Pharmaceuticals Inc filed Critical Quanticel Pharmaceuticals Inc
Publication of SG11201504946VA publication Critical patent/SG11201504946VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
SG11201504946VA 2012-12-21 2013-12-23 Histone demethylase inhibitors SG11201504946VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745246P 2012-12-21 2012-12-21
US201361785380P 2013-03-14 2013-03-14
PCT/US2013/077539 WO2014100818A1 (en) 2012-12-21 2013-12-23 Histone demethylase inhibitors

Publications (1)

Publication Number Publication Date
SG11201504946VA true SG11201504946VA (en) 2015-07-30

Family

ID=50979314

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504946VA SG11201504946VA (en) 2012-12-21 2013-12-23 Histone demethylase inhibitors

Country Status (23)

Country Link
US (12) US8952151B2 (en)
EP (1) EP2935217B1 (en)
JP (1) JP6273621B2 (en)
KR (1) KR20150100814A (en)
CN (1) CN105026372B (en)
AU (1) AU2013363957B2 (en)
BR (1) BR112015014968A2 (en)
CA (1) CA2895808A1 (en)
CL (1) CL2015001771A1 (en)
CR (1) CR20150368A (en)
EA (1) EA028774B1 (en)
EC (1) ECSP15030527A (en)
ES (1) ES2718495T3 (en)
HK (1) HK1210611A1 (en)
IL (1) IL239510A0 (en)
MX (1) MX2015007997A (en)
NI (1) NI201500088A (en)
PE (1) PE20151417A1 (en)
PH (1) PH12015501464A1 (en)
SA (1) SA515360657B1 (en)
SG (1) SG11201504946VA (en)
WO (1) WO2014100818A1 (en)
ZA (1) ZA201505007B (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6530313B2 (en) 2012-10-02 2019-06-12 エピセラピューティクス アーペーエス Inhibitors of histone demethylase
CN105026372B (en) 2012-12-21 2018-06-05 赛尔基因昆蒂赛尔研究公司 Histone demethylase inhibitors
EA201590943A1 (en) 2012-12-21 2016-01-29 Алиос Биофарма, Инк. SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES
BR112015020650A2 (en) 2013-02-27 2017-07-18 Epitherapeutics Aps histone demethylase inhibitors
TWI627174B (en) 2013-03-14 2018-06-21 比利時商健生藥品公司 P2x7 modulators
EP2970304B1 (en) 2013-03-14 2018-08-15 Janssen Pharmaceutica NV P2x7 modulators
TWI599567B (en) 2013-03-14 2017-09-21 健生藥品公司 P2x7 modulators
GEP201706780B (en) 2013-03-14 2017-11-27 Boehringer Ingelheim Int Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014152589A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
KR102359214B1 (en) 2014-04-04 2022-02-07 델 마 파마슈티컬스 Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
SI3160952T1 (en) 2014-06-25 2021-07-30 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
BR112017003433B1 (en) 2014-09-12 2023-11-14 Boehringer Ingelheim International Gmbh SPIROCYCLIC CATEPSIN C INHIBITORS, PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
KR20170048591A (en) 2014-09-17 2017-05-08 셀젠 콴티셀 리서치, 인크. Histone demethylase inhibitors
US10030017B2 (en) 2014-09-17 2018-07-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017117154A1 (en) 2015-12-28 2017-07-06 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
ES2921009T3 (en) * 2016-03-15 2022-08-16 Celgene Quanticel Res Inc Histone demethylase inhibitors
KR101725292B1 (en) 2016-03-30 2017-04-10 한국과학기술연구원 Novel Pyrimidine-4-Carboxylic Acid Derivatives Having Anti-tumor Activity
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017198785A1 (en) * 2016-05-18 2017-11-23 Ieo - Istituto Europeo Di Oncologia S.R.L. Oxime derivatives useful as inhibitors of histone demethylase kdm4c
SG11201809893WA (en) 2016-05-27 2018-12-28 Gilead Sciences Inc Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
BR102017010009A2 (en) 2016-05-27 2017-12-12 Gilead Sciences, Inc. COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
ES2906581T3 (en) 2016-09-02 2022-04-19 Gilead Sciences Inc Toll-like receptor modulator compounds
ES2826748T3 (en) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivatives of 4,6-diamino-pyrido [3,2-d] pyrimidine as modulators of Toll-like receptors
CN110023495A (en) 2016-10-14 2019-07-16 精密生物科学公司 To the engineering meganuclease of the identification sequence-specific in Hepatitis B virus-DNA
TWI820984B (en) 2017-01-31 2023-11-01 美商基利科學股份有限公司 Crystalline forms of tenofovir alafenamide
JOP20180008A1 (en) 2017-02-02 2019-01-30 Gilead Sciences Inc Compounds for the treatment of hepatitis b virus infection
EP3600301B1 (en) * 2017-03-30 2024-07-03 Albert-Ludwigs-Universität Freiburg Kdm4 inhibitors
JOP20180040A1 (en) 2017-04-20 2019-01-30 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
UY37774A (en) * 2017-06-19 2019-01-31 Novartis Ag SUBSTITUTED 5-CYANOINDOL COMPOUNDS AND USES OF THE SAME
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7098748B2 (en) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. 2'3'cyclic dinucleotide with phosphonate binding that activates the STING adapter protein
CN118084940A (en) 2018-02-13 2024-05-28 吉利德科学公司 PD-1/PD-L1 inhibitors
ES2962605T3 (en) 2018-02-26 2024-03-20 Gilead Sciences Inc Substituted pyrrolizine compounds as inhibitors of HBV replication
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (en) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
TWI833744B (en) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-cyclic dinucleotides
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TW202014193A (en) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 2’3’-cyclic dinucleotides comprising carbocyclic nucleotide
CR20210013A (en) 2018-07-13 2021-02-26 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
AU2019349962A1 (en) 2018-09-28 2021-03-18 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CA3117199C (en) 2018-10-24 2024-03-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
BR112021008255A2 (en) 2018-10-31 2021-08-03 Gilead Sciences, Inc. substituted 6-azabenzimidazole compounds as hpk1 inhibitors
CN117105933A (en) 2018-10-31 2023-11-24 吉利德科学公司 Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
CN113543851A (en) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2'3' -cyclic dinucleotides and their prodrugs
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3935066A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
TW202210480A (en) 2019-04-17 2022-03-16 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI751517B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
AU2020301161B2 (en) 2019-06-25 2023-10-26 Gilead Sciences, Inc. FLT3L-Fc fusion proteins and methods of use
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
KR20220074917A (en) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 HBV vaccines and methods of treating HBV
EP4038070A1 (en) 2019-09-30 2022-08-10 Janssen Pharmaceutica NV Radiolabelled mgl pet ligands
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN115605493A (en) 2020-03-20 2023-01-13 吉利德科学公司(Us) Prodrugs of4'-C-substituted-2-halo-2' -deoxyadenosine nucleosides and methods of making and using the same
MX2022011902A (en) 2020-03-26 2023-01-04 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators.
BR112023002164A2 (en) 2020-08-07 2023-03-14 Gilead Sciences Inc PHOSPHONAMIDE NUCLEOTIDE ANALOG PRODRUGS AND THEIR PHARMACEUTICAL USE
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
AU2022297373A1 (en) 2021-06-23 2024-01-04 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP2024522698A (en) 2021-06-23 2024-06-21 ギリアード サイエンシーズ, インコーポレイテッド Diacylglycerol kinase modulating compounds
KR20240005901A (en) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
CN117377671A (en) 2021-06-23 2024-01-09 吉利德科学公司 Diacylglycerol kinase modulating compounds
CN114907318B (en) * 2022-07-04 2023-08-11 郑州大学 Isonicotinic acid-pyrazole derivative and preparation method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195537B1 (en) 2000-10-05 2003-03-12 Ford Global Technologies, Inc., A subsidiary of Ford Motor Company Transmission double clutch with two input shafts
US7595343B2 (en) 2001-09-14 2009-09-29 Methylgene, Inc. Inhibitors of histone deacetylase
UA89035C2 (en) 2003-12-03 2009-12-25 Лео Фарма А/С Hydroxamic acid esters and pharmaceutical use thereof
DE102004039876A1 (en) 2004-06-23 2006-01-26 Lanxess Deutschland Gmbh Preparation of fluorinated 1,3-benzodioxanes
AR059733A1 (en) 2006-03-07 2008-04-23 Smithkline Beecham Corp COMPOSITE DERIVED FROM GLYCIN N- REPLACED WITH BICYCLE HETEROAROMATICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE TO PREPARE A MEDICINAL PRODUCT TO TREAT ANEMIA AND PROCESS FOR PREPARATION
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
GB201112607D0 (en) * 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2013143597A1 (en) * 2012-03-29 2013-10-03 Glaxo Group Limited Demethylase enzymes inhibitors
WO2014089368A1 (en) 2012-12-05 2014-06-12 Bio-Rad Laboratories, Inc Methods for polymerase chain reaction copy number variation assays
ES2658597T3 (en) 2012-12-19 2018-03-12 Celgene Quanticel Research, Inc. Histone Demethylase Inhibitors
CN105026372B (en) 2012-12-21 2018-06-05 赛尔基因昆蒂赛尔研究公司 Histone demethylase inhibitors
SI3160952T1 (en) * 2014-06-25 2021-07-30 Celgene Quanticel Research, Inc. Histone demethylase inhibitors

Also Published As

Publication number Publication date
HK1210611A1 (en) 2016-04-29
EP2935217A4 (en) 2016-06-01
CL2015001771A1 (en) 2016-01-04
US11214542B2 (en) 2022-01-04
US9447045B2 (en) 2016-09-20
CA2895808A1 (en) 2014-06-26
US20160347714A1 (en) 2016-12-01
US9828343B2 (en) 2017-11-28
AU2013363957B2 (en) 2018-03-22
EP2935217B1 (en) 2019-02-27
CN105026372A (en) 2015-11-04
NI201500088A (en) 2016-02-15
BR112015014968A2 (en) 2017-07-11
US20170158681A1 (en) 2017-06-08
CR20150368A (en) 2015-09-30
US20150119397A1 (en) 2015-04-30
US10807956B2 (en) 2020-10-20
WO2014100818A1 (en) 2014-06-26
ECSP15030527A (en) 2016-01-29
US8952151B2 (en) 2015-02-10
US20170298025A1 (en) 2017-10-19
US20210009520A1 (en) 2021-01-14
US9085534B2 (en) 2015-07-21
EP2935217A1 (en) 2015-10-28
US11639333B2 (en) 2023-05-02
AU2013363957A1 (en) 2015-07-16
US20160115131A1 (en) 2016-04-28
ZA201505007B (en) 2017-07-26
JP6273621B2 (en) 2018-02-07
EA201591145A1 (en) 2015-12-30
US20180044296A1 (en) 2018-02-15
US20150291529A1 (en) 2015-10-15
SA515360657B1 (en) 2018-06-24
US9725441B2 (en) 2017-08-08
CN105026372B (en) 2018-06-05
PE20151417A1 (en) 2015-10-10
US10179769B2 (en) 2019-01-15
US20230286917A1 (en) 2023-09-14
US10597365B2 (en) 2020-03-24
IL239510A0 (en) 2015-08-31
KR20150100814A (en) 2015-09-02
EA028774B1 (en) 2017-12-29
PH12015501464A1 (en) 2015-09-21
US9611221B2 (en) 2017-04-04
US20190077758A1 (en) 2019-03-14
US20200172485A1 (en) 2020-06-04
US20140213591A1 (en) 2014-07-31
ES2718495T3 (en) 2019-07-02
JP2016503809A (en) 2016-02-08
MX2015007997A (en) 2016-02-18

Similar Documents

Publication Publication Date Title
HK1210611A1 (en) Histone demethylase inhibitors
HUE037312T2 (en) Histone demethylase inhibitors
EP2928471A4 (en) Histone demethylase inhibitors
IL253259A0 (en) Inhibitors of histone demethylases
HK1212681A1 (en) Glucosylceramide synthase inhibitors
EP2969007A4 (en) Histone demethylase inhibitors
PT2970211T (en) Histone demethylase inhibitors
HK1209422A1 (en) Fbxo3 inhibitors fbxo3
HK1247920A1 (en) Inhibitors of histone demethylases